

DAFTAR PUSTAKA

- Bailey, L.C., Lange, B.J., Rheingold, S.R., Bunin, N.J., 2008. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. *Lancet Oncol.* 9: 873–883.
- Bernard, S.C., Abdelsamad, E.H., Johnson, P.A., Chapman, D.L., Parvathaneni, M., 2017. Pediatric Leukemia : Diagnosis to treatment - A review. *J. Cancer Clin. trials* 2: 2–4.
- Bonney, D.K., 2012. An update on leukaemia. *Paediatr. Child Health (Oxford)*. 22: 85–91.
- Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N., Camitta, B.M., 2008. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study. *Blood* 111: 5477–5485.
- Borst, L., Wallerek, S., Dalhoff, K., Rasmussen, K.K., Wesenberg, F., Wehner, P.S., Schmiegelow, K., 2011. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. *Eur. J. Haematol.* 86: 477–483.
- Brüggemann, M., Gökbuget, N., Kneba, M., 2012. Acute lymphoblastic leukemia: Monitoring minimal residual disease as a therapeutic principle. *Semin. Oncol.* 39: 47–57.
- Campana, D., 2009. Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia. *Hematol. Oncol. Clin. North Am.* 23: 1083–1098.
- Campana, D., Pui, C.-H., 2013. Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia. *Neoplast. Dis. blood* 305–329.
- Cave, H., 1998. Clinical significance of minimal residual disease in leukemia. *N. Engl. J. Med.* 339: 591–598.
- Cavé, H., Bosch, J., Suci, S., Jacques, O., Vilmer, E., 1998. Clinical Significance of Minimal Residual Disease in Childhood. *N. Engl. J. Med.* 339: 591–598.

- Chessells, J.M., Hall, E., Prentice, H.G., Durrant, J., Bailey, C.C., Richards, S.M., 1998. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties. *Leukemia* 12: 463–473.
- Choi, J.K., 2014. Pathogenesis of Pediatric Acute Lymphoblastic Leukemias. *Pathobiol. Hum. Dis. A Dyn. Encycl. Dis. Mech.* 1749–1758.
- Conter, V., Bartram, C., Grazia, M., Schrauder, A., Pabzer, Re., Moricke, A., Arico, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Baarisone, E., Henze, G., Schrappe, M., 2010. Molecular response to treatment redefines all prognostic factors in children and adolescents with Bcell lprecursor acute lymphoblastic leukemia resultsin 3184 patients of the AIEOP BFMALL 2000 study. *Blood* 115: 3206–3214.
- Cooper, S., Brown, P., 2015. Treatment of Pediatric Acute Lymphoblastic Leukemia. *Pediatr Clin North Am* 62: 61–73.
- Cortes, J., Fayad, L., Brien, S.O., Keating, M., Kantarjian, H., 1999. Persistence of Peripheral Blood and Bone Marrow Blasts during Remission Induction in Adult Acute Lymphoblastic Leukemia Confers a Poor Prognosis Depending on Treatment Intensity 5: 2491–2497.
- Coustan-Smith, E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H., Campana, D., 2002. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. *Blood* 100: 52–58.
- Flohr, T., Schrauder, A., Cazzaniga, G., 2008. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multi ... Minimal residual disease-directed risk stratification using real-time. *Leukemia* 22: 771–782.
- Gajjar, a, Ribeiro, R., Hancock, M., 1995. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. *Blood* 86: 1292–5.

- Garvin, J.H., 2004. Gender-Specific Aspects of Pediatric Hematology and Oncology, Principles of Gender-Specific Medicine. Elsevier Inc.
- Gaynon, P.S., Trigg, M.E., Heerema, N.A., Sensel, M.G., Sather, H.N., Hammond, G.D., Bleyer, W.A., 2000. Children's cancer group trials in childhood acute lymphoblastic leukemia: 1983-1995. *Leukemia* 14: 2223–2233.
- Gerr, H., Zimmermann, M., Schrappe, M., Dworzak, M., Ludwig, W.D., Bradtke, J., Moericke, A., Schabath, R., Creutzig, U., Reinhardt, D., 2010. Acute leukaemias of ambiguous lineage in children: Characterization, prognosis and therapy recommendations. *Br. J. Haematol.* 149: 84–92.
- Han, X., Bueso-ramos, C.E., 2005. Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. *Ann. Diagn. Pathol.* 9: 239–257.
- Ishio, T., Sugita, J., Tateno, T., Hidaka, D., Hayase, E., Shiratori, S., Okada, K., Goto, H., Onozawa, M., Nakagawa, M., Hashimoto, D., Kahata, K., Fujimoto, K., Endo, T., Kondo, T., Teshima, T., 2018. Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources. *Biol. Blood Marrow Transplant.* 24: 1990–1996.
- Jaime-Pérez, J.C., López-Razo, O.N., García-Arellano, G., Pinzón-Uresti, M.A., Jiménez-Castillo, R.A., González-Llano, O., Gómez-Almaguer, D., 2016. Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico. *Arch. Med. Res.* 47: 668–676.
- Kamps, W.A., Veerman, A.J.P., Van Wering, E.R., Van Weerden, J.F., Slater, R., Van Der Does-Van Den Berg, A., 2000. Long-term follow-up of Dutch childhood leukemia study group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. *Leukemia* 14: 2240–2246.
- Lanskowsky, P., Lipton, J.M., Fish, J.D., 2016. Lanzkowsky's manual of pediatric hematology and oncology, sixth ed., 6th editio. ed, academic press elsevier. London.
- Lustosa de Sousa, D.W., de Almeida Ferreira, F.V., Cavalcante Félix, F.H., de Oliveira Lopes, M.V., 2015. Acute lymphoblastic leukemia in children and adolescents:

- Prognostic factors and analysis of survival. *Rev. Bras. Hematol. Hemoter.* 37: 223–229.
- Lwanga, K., Lemeshow, S., 1990. SAMPLE SIZE DETERMINATION IN HEALTH STUDIES A Practical Manual. *World Heal. Organ. Geneva* 1.
- Mchugh, M.L., 2012. Interrater reliability : the kappa statistic. *Biochem. Medica* 22: 276–282.
- Mertens, F., Johansson, B., Mitelman, F., 1993. Age- and gender-related heterogeneity of cancer chromosome aberrations. *Cancer Genet. Cytogenet.* 70: 6–11.
- Mitchell, C., Payne, J., Wade, R., Vora, A., Kinsey, S., Richards, S., Eden, T., 2009. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: Results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. *Br. J. Haematol.* 146: 424–436.
- Möricke, A., Zimmermann, M., Reiter, A., Gadner, H., Odenwald, E., Harbott, J., Ludwig, W.D., Riehm, H., Schrappe, M., 2005. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: Data from the trials ALL-BFM 86, 90, and 95. *Klin. Padiatr.* 217: 310–320.
- Oskarsson, T., Söderhäll, S., Arvidson, J., Forestier, E., Montgomery, S., Bottai, M., Lausen, B., Carlsen, N., Hellebostad, M., Lähteenmäki, P., Saarinen-Pihkala, U.M., G.Jónsson, Ó., Heyman, M., 2016. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: Prognostic factors, treatment and outcome. *Haematologica* 101: 68–76.
- Pui, C.H., 2000. Acute lymphoblastic leukemia in children. *Curr. Opin. Oncol.* 12: 3–12.
- Richards, S., Gray, R., Peto, R., Gaynon, P., Masera, G., Pession, A., Rondelli, R., Valsecchi, M.G., Reiter, A., Riehm, H., Schrappe, M., McIntyre, O.R., Bleyer, A., Cairo, M., Gaynon, P., Reaman, G., Sather, H., Trigg, M., Auclerc, M.F., 1996. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children. *Lancet* 347: 1783–1788.

- Sandlund, J.T., Harrison, P.L., Rivera, G., Behm, F.G., Head, D., Boyett, J., Rubnitz, J.E., Gajjar, A., Raimondi, S., Ribeiro, R., Hudson, M., Relling, M., Evans, W., Pui, C.H., 2002. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. *Blood* 100: 43–47.
- Schrapppe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E., Riehm, H., 2000. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. *Leukemia* 14: 2205–2222.
- Stanulla, M., Schrapppe, M., 2009. Treatment of Childhood Acute Lymphoblastic Leukemia. *Semin. Hematol.* 46: 52–63.
- Supriyadi, E., 2011. incidence of childhood leukemia in Yogyakarta, Indonesia, 1998-2009. *Pediatr. blood cancer* 57: 588–593.
- Vora, A., 2016. Childhood leukaemia: An update. *Paediatr. Child Heal. (United Kingdom)* 26: 51–56.
- Wang, L., Bhatia, S., Gomez, S.L., Yasui, Y., 2015. Differential Inequality Trends Over Time in Survival Among U.S. Children with Acute Lymphoblastic Leukemia by Race/Ethnicity, Age at Diagnosis, and Sex. *Cancer Epidemiol Biomarkers Prev.* 24: 1781–1788.
- Wartenberg, D., Groves, F.D., Adelman, A., 2008. Acute Lymphoblastic Leukemia: Epidemiology and Etiology, in: Hematologic Malignancies: Acute Leukemias. Springer, Berlin, pp. 77–93.
- Yang, X., Lu, J., He, H., Wang, Y., Zhao, W., Xiao, P., Li, J., Li, J., Lv, H., Sun, Y., Fan, J., Chai, Y.H., Hu, S.Y., 2016. Complications and outcomes of pediatric patients with hyperleukocytic acute lymphoblastic leukemia with CCLG-2008 protocol. *Int. J. Clin. Exp. Med.* 9: 3324–3333.